{"id":127794,"date":"2022-02-22T10:05:07","date_gmt":"2022-02-22T15:05:07","guid":{"rendered":"https:\/\/44.250.171.167\/?p=127794"},"modified":"2022-10-05T06:08:13","modified_gmt":"2022-10-05T10:08:13","slug":"orchid-pharma-ltd-q3-fy22-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-q3-fy22-earnings-conference-call-insights\/","title":{"rendered":"Orchid Pharma Ltd Q3 FY22 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Orchid Pharma Ltd Q3 FY22 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/z2DK9xz1c8k?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Orchid Pharma Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/ORCHPHARMA\/\">ORCHPHARMA<\/a>) Q3 FY22 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Viraj Kacharia\u00a0 from Securities Investment asked about the DLL performance for the nine months of FY23 and comparison to previous year. Sunil Gupta CFO said that nine month EBITDA is INR10 crore and sale was INR300 crore.<\/li>\n<\/ul>\n<ul>\n<li>Viraj Kacharia\u00a0 of Securities Investment also asked about the capex of INR50 crores for biotech, chemicals and intermediaries and what are the products and size of these products. Mridul Dhanuka Director said that right now it\u2019s only an exploratory one and there is no committed investment in biotech, nothing concrete on that front to say now.<\/li>\n<\/ul>\n<ul>\n<li>Nikhil Upadhyay with SIMPL asked that the company saw good growth in 3Q22 and if it was more price lead or demand lead. Mridul Dhanuka Director said that during 3Q22 the company has not been able to increase price, it\u2019s largely due to increase in demand. In last two quarters, in Europe the demand was very much subdued. This demand increased in 3Q22.<\/li>\n<\/ul>\n<ul>\n<li>Himanshu Upadhyay from O3 Capital asked about the position of company versus competitor on the API business. Mridul Dhanuka Director replied that Dhanuka Labs cost competency is most efficient in terms of percentages. However, as it operates in the RoW markets there is cost pressure on margins. Additionally, process efficiencies are also high compared to competitors. There is also focus on some of the new Cephalosporin that only Dhanuka Labs has prominence in the market.<\/li>\n<\/ul>\n<ul>\n<li>Himanshu Upadhyay from O3 Capital also queried about the order book percentage growth QonQ and YoY. Mridul Dhanuka Director answered that based on the earlier guidance, the company would maintain 20% CAGR kind of number and the order book is in line with that number and hope to continue to grow that.<\/li>\n<\/ul>\n<ul>\n<li>Himanshu Upadhyay from O3 Capital also asked which are the largest molecules in Cephalosporin and the fastest growing products. Mridul Dhanuka Director replied that generally speaking most of the prominent large volume molecules, Dhanuka and Orchid combined would have percentage share between 20-35% depending on molecule volume.<\/li>\n<\/ul>\n<ul>\n<li>Tarang Agrawal of Old Bridge Capital asked how volumes have grown in 3Q22 on a YonY basis and nine month basis for Orchid and DLL. Mridul Dhanuka Director answered that the growth was entirely volume led. In 3Q22, the company did well by growing by 60%. For nine month, the number looks like 20% in Orchid. In DLL, on a volume basis it\u2019s like 8-10%.<\/li>\n<\/ul>\n<ul>\n<li>Tarang Agrawal of Old Bridge Capital also enquired about raw material contribution. \u00a0Mridul Dhanuka Director said most of those are materials that come from China, like fermentation products. And these products contribute to the total COGS depending on the product 70% of the COGS would come from these products in China.<\/li>\n<\/ul>\n<ul>\n<li>Viraj Parekh with Carnelian Asset Advisors enquired about performance of Non-Penicillin, Non-Cephalosporin (NPNC) segment in DLL for the nine months. Mridul Dhanuka Director said that out of the INR300 crores DLL did about INR100 crore of NPNC versus INR80 crores in last year same period.<\/li>\n<\/ul>\n<ul>\n<li>Viraj Parekh with Carnelian Asset Advisors asked about plant capacity utilization for 3Q22. Mridul Dhanuka Director replied that the company has tried to utilize the sterile capacities to the full in Orchid and looking at some investment to increase capacity by another 25%. In Dhanuka, the capacity utilization in NPNC has improved by 10%. Dhanuka Lab remains largely same or slightly reduced.<\/li>\n<\/ul>\n<ul>\n<li>Viraj Parekh with Carnelian Asset also asked how and when the company plans to reduce the promoter stake to 75% and is the sale of Orchid Tower expected to be completed in FY22. Mridul Dhanuka Director said it depends on how SEBI advises to do and there is time till 31 March, 2023. The intent is to do it once the merger is complete and well before the timeline. Orchid Tower, if not this quarter, by next quarter it will be sold.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Orchid Pharma Ltd (ORCHPHARMA) Q3 FY22 Earnings Concall Q&amp;A Highlights: Viraj Kacharia\u00a0 from Securities Investment asked about the DLL performance for the nine months of FY23 and comparison to previous year. Sunil Gupta CFO said that nine month EBITDA is INR10 crore and sale was INR300 crore. Viraj Kacharia\u00a0 of Securities Investment [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-127794","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":143178,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":127794,"position":0},"title":"Orchid Pharma Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"March 6, 2023","format":false,"excerpt":"Key highlights from Orchid Pharma Ltd (ORCHPHARMA) Q3 FY23 Earnings Concall Q&A Highlights: [00:04:43] Himanshu Upadhyay from o3 Capital asked what changed in the DLL and Orchid merger that the merger opinion has been reversed. Manish Dhanuka MD said that the basic philosophy and intent behind the merger has not\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":143254,"url":"https:\/\/alphastreet.com\/india\/fiem-industries-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":127794,"position":1},"title":"Fiem Industries Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"March 14, 2023","format":false,"excerpt":"Key highlights from Fiem Industries Ltd (FIEMIND) Q3 FY23 Earnings Concall Management Update: [00:04:10] FIEMIND said it achieved highest ever sales and profits for the first nine months of FY23. LED shares as a percentage of total automotive lighting touched 50%, and EVs grew more than 3 times over last\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":137018,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":127794,"position":2},"title":"Orchid Pharma Ltd Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 22, 2022","format":false,"excerpt":"Key highlights from Orchid Pharma Ltd (ORCHPHARMA) Q2 FY23 Earnings Concall Q&A Highlights: [00:05:20] Rupesh Jain from Intelsense Capital asked about capacity utilization in 1H23. Mridul Dhanuka Director replied that on the sterile plant the utilization roughly is 90%. And the oral plant it\u2019s about 70%. [00:08:27] Rupesh Jain from\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":127005,"url":"https:\/\/alphastreet.com\/india\/jubilant-ingrevia-ltd-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":127794,"position":3},"title":"Jubilant Ingrevia Ltd Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 2, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=VEV5IjVrTNI Key highlights from Jubilant Ingrevia Ltd (JUBLINGREA) Q3 FY22 Earnings Concall Management Update: JUBLINGREA commented that with its capex plans shaping up, it is on course of doubling the revenue by FY26 from the base of FY21. For FY23 capex is expected to be around INR300 crore. Q&A Highlights:\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":128954,"url":"https:\/\/alphastreet.com\/india\/privi-speciality-chemicals-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":127794,"position":4},"title":"Privi Speciality Chemicals Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 9, 2022","format":false,"excerpt":"https:\/\/youtu.be\/Jfcmzb7kXAs Key highlights from Privi Speciality Chemicals Ltd (PRIVISCL) Q4 FY22 Earnings Concall Q&A Highlights: Manish Gupta from Solidarity Advisors asked that when PRIVISCL can commercialize its first biotech product. Narayan Iyer CFO said that it expect its experience in the biotech space to give the company a positive output\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":127320,"url":"https:\/\/alphastreet.com\/india\/gujarat-narmada-valley-fertilizers-and-chemicals-ltd-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":127794,"position":5},"title":"Gujarat Narmada Valley Fertilizers and Chemicals Ltd Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 14, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=kVky-HKq_to&t=73s Key highlights from Gujarat Narmada Valley Fertilizers and Chemicals Ltd (GNFC) Q3 FY22 Earnings Concall Management Update: The company said there have been significant developments internationally and domestically comparing 2Q22 to 3Q22. Internationally, energy prices are on the wild, be it gas, oil or coal. Though these prices should\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/127794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=127794"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/127794\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=127794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=127794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=127794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}